title: The Fanconi anemia polypeptide FACC is localized to the cytoplasm.
abstract: Fanconi anemia (FA) is an autosomal recessive disease characterized by congenital anomalies, aplastic anemia, and chromosomal instability. A cDNA encoding the FA complementation group C (FACC) polypeptide was recently cloned [Strathdee, C. A., Gavish, H., Shannon, W. R. & Buchwald, M. (1992) Nature (London) 356, 763-767]. To further characterize this polypeptide, we generated a rabbit polyclonal antiserum against its carboxyl terminus. We used this antiserum to analyze the FACC polypeptide from normal or mutant (FA) lymphoblast cell lines. By immunoprecipitation, the wild-type FACC was a 60-kDa protein, consistent with its predicted molecular mass. FA group C cell lines expressed full-length FACC, truncated FACC, or no detectable FACC polypeptide. In addition, the antiserum specifically immunoprecipitated a 50-kDa and a 150-kDa FACC-related protein (FRP-50 and FRP-150). Unexpectedly, cell fractionation and immunofluorescence studies demonstrated that the FACC polypeptide localizes to the cytoplasm. In conclusion, we have generated an antiserum specific for the human FACC polypeptide. The antiserum should be useful for screening FA cells for mutant FACC polypeptides and for identifying and cloning FACC-related proteins.
authors.affiliation: Division of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
authors.forename: T
authors.initials: T
authors.lastname: Yamashita
authors.forename: D L
authors.initials: DL
authors.lastname: Barber
authors.forename: Y
authors.initials: Y
authors.lastname: Zhu
authors.forename: N
authors.initials: N
authors.lastname: Wu
authors.forename: A D
authors.initials: AD
authors.lastname: D'Andrea
mesh_terms: D001483:Base Sequence; D018797:Cell Cycle Proteins; D002458:Cell Fractionation; D002460:Cell Line; D002461:Cell Line, Transformed; D002470:Cell Survival / Q000187:drug effects; D017931:DNA Primers; D004268:DNA-Binding Proteins; D000939:Epitopes / Q000032:analysis; D005091:Exons; D005199:Fanconi Anemia / Q000235:genetics* / Q000378:metabolism*; D052218:Fanconi Anemia Complementation Group C Protein; D051856:Fanconi Anemia Complementation Group Proteins; D005455:Fluorescent Antibody Technique; D005816:Genetic Complementation Test; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D006389:Hemagglutinins, Viral / Q000032:analysis / Q000096:biosynthesis; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D008715:Methionine / Q000378:metabolism; D016685:Mitomycin / Q000633:toxicity; D008969:Molecular Sequence Data; D008970:Molecular Weight; D009154:Mutation; D009687:Nuclear Proteins; D010641:Phenotype; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D014176:Protein Biosynthesis; D011506:Proteins / Q000032:analysis; D017384:Sequence Deletion; D014759:Viral Envelope Proteins / Q000032:analysis / Q000096:biosynthesis
chemical_list: D018797:Cell Cycle Proteins; D017931:DNA Primers; D004268:DNA-Binding Proteins; D000939:Epitopes; C497651:FANCC protein, human; D052218:Fanconi Anemia Complementation Group C Protein; D051856:Fanconi Anemia Complementation Group Proteins; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D006389:Hemagglutinins, Viral; D009687:Nuclear Proteins; D011506:Proteins; D014759:Viral Envelope Proteins; D016685:Mitomycin; D008715:Methionine